A genome-wide analysis sheds light on how hormone response in endometrial cells affects endometrial function.
The endometrium is a dynamic tissue that undergoes dynamic cyclic proliferation and differentiation to prepare for pregnancy. Endometrial stromal fibroblasts (eSFs) are key regulators of pregnancy success.
How the cells interact with circulating levels of ovarian-derived estradiol (E2) and progesterone (P4) is unknown. Results of a new genome-wide analysis suggest that the complex interplay between eSFs, E2 and P4 has a significant impact on endometrial function or dysfunction1.
To further understand the dynamic interactions, a team of researchers studied the effects of E2, P4, and their combination (E2+P4) on the DNA methylome and transcriptome and their interplay in normal eSF.
The effects on the cells were analyzed at 14 days of exposure to the hormones, mimicking the timeframe of a typical menstrual cycle.
The cells used in the study were derived from women with and without endometriosis. Those without the disease and who had no known gynecologic or systemic disorders served as the study’s control group.
Researchers only included endometrial samples from extensively screened volunteers without any gynecologic disorders and no uterine pathology (NUP), with confirmed in vitro eSF progesterone responsiveness.
The researchers investigated 485,577 methylation targets across the genome and found that E2 and P4 alone and in combination affected the DNA methylome to varying extents and with distinct patterns in eSF.
Related: Impact of endometrial thickness and abnormal uterine bleeding on endometrial cancer
The study also showed that hormone-DNA methylome dynamics differ under normal and disease conditions, and that the stage of endometriosis affects the hormone-methylome response. The most blunted response to the hormones was seen in cells from women with advanced endometriosis.
Novel responses to E2 that had not reported before were seen in eSFs from women with the disease. The different aberrant DNA methylation signatures in eSFs from the group with endometriosis suggest that there are distinct subtypes of the disease.
__
__
Image credit: By Nephron - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=18158244
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More